Download PDF
Semin Liver Dis 2016; 36(04): 340-348
DOI: 10.1055/s-0036-1594007
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Microbiome and Primary Sclerosing Cholangitis

Ahmad H. Ali
1   Division of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, Arizona
,
Elizabeth J. Carey
1   Division of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, Arizona
,
Keith D. Lindor
1   Division of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, Arizona
2   College of Health Solutions, Arizona State University, Tempe, Arizona
› Author Affiliations
Further Information

Publication History

Publication Date:
20 December 2016 (online)

    Permissions and Reprints

Abstract

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease with detrimental sequela. In many patients, PSC progresses to end-stage liver disease and hepatobiliary cancer. There is no medical therapy that is proven to halt or reverse the progression of PSC. Approximately 70 to 80% of PSC patients have inflammatory bowel disease, usually ulcerative colitis. The etiology of PSC is poorly understood. Several lines of evidence suggest that the intestinal microbiota plays an important role in the etiopathogenesis of PSC. Stemming from this theory, several antibiotics have been tried in PSC, some of which had shown promising results. Fecal microbiota transplantation is a novel therapy, and is currently being investigated as a potential therapeutic strategy in PSC along with probiotics. In this article, the authors discuss the current knowledge of the intestinal microbiota in PSC.

Keywords

primary sclerosing cholangitis - microbiota - genome-wide association studies - antibiotics
 

  • References

  • 1 Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. Lancet 2013; 382 (9904) 1587-1599
    CrossrefPubMedGoogle Scholar
  • 2 Bambha K, Kim WR, Talwalkar J , et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003; 125 (5) 1364-1369
    CrossrefPubMedGoogle Scholar
  • 3 Brandsaeter B, Broomé U, Isoniemi H , et al. Liver transplantation for primary sclerosing cholangitis in the Nordic countries: outcome after acceptance to the waiting list. Liver Transpl 2003; 9 (9) 961-969
    CrossrefPubMedGoogle Scholar
  • 4 Bjøro K, Brandsaeter B, Foss A, Schrumpf E. Liver transplantation in primary sclerosing cholangitis. Semin Liver Dis 2006; 26 (1) 69-79
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Olsson R, Boberg KM, de Muckadell OS , et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005; 129 (5) 1464-1472
    CrossrefPubMedGoogle Scholar
  • 6 Lindor KD, Kowdley KV, Luketic VA , et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009; 50 (3) 808-814
    CrossrefPubMedGoogle Scholar
  • 7 Chapman R, Fevery J, Kalloo A , et al; American Association for the Study of Liver Diseases. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51 (2) 660-678
    CrossrefPubMedGoogle Scholar
  • 8 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51 (2) 237-267
    CrossrefPubMedGoogle Scholar
  • 9 Bergquist A, Montgomery SM, Bahmanyar S , et al. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2008; 6 (8) 939-943
    CrossrefPubMedGoogle Scholar
  • 10 Henriksen EK, Melum E, Karlsen TH. Update on primary sclerosing cholangitis genetics. Curr Opin Gastroenterol 2014; 30 (3) 310-319
    CrossrefPubMedGoogle Scholar
  • 11 Liu JZ, Hov JR, Folseraas T , et al; UK-PSCSC Consortium; International PSC Study Group; International IBD Genetics Consortium. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet 2013; 45 (6) 670-675
    CrossrefPubMedGoogle Scholar
  • 12 Ellinghaus D, Folseraas T, Holm K , et al. Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4. Hepatology 2013; 58 (3) 1074-1083
    PubMedGoogle Scholar
  • 13 Jacobs JP, Braun J. Immune and genetic gardening of the intestinal microbiome. FEBS Lett 2014; 588 (22) 4102-4111
    CrossrefPubMedGoogle Scholar
  • 14 Folseraas T, Melum E, Rausch P , et al. Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. J Hepatol 2012; 57 (2) 366-375
    CrossrefPubMedGoogle Scholar
  • 15 Koenig JE, Spor A, Scalfone N , et al. Succession of microbial consortia in the developing infant gut microbiome. Proc Natl Acad Sci U S A 2011; 108 (Suppl. 01) 4578-4585
    CrossrefPubMedGoogle Scholar
  • 16 Krajmalnik-Brown R, Ilhan ZE, Kang DW, DiBaise JK. Effects of gut microbes on nutrient absorption and energy regulation. Nutr Clin Pract 2012; 27 (2) 201-214
    CrossrefPubMedGoogle Scholar
  • 17 Cantarel BL, Coutinho PM, Rancurel C, Bernard T, Lombard V, Henrissat B. The Carbohydrate-Active EnZymes database (CAZy): an expert resource for glycogenomics. Nucleic Acids Res 2009; 37 (Database issue) D233-D238
    CrossrefPubMedGoogle Scholar
  • 18 LeBlanc JG, Milani C, de Giori GS, Sesma F, van Sinderen D, Ventura M. Bacteria as vitamin suppliers to their host: a gut microbiota perspective. Curr Opin Biotechnol 2013; 24 (2) 160-168
    CrossrefPubMedGoogle Scholar
  • 19 Ramakrishna BS. Role of the gut microbiota in human nutrition and metabolism. J Gastroenterol Hepatol 2013; 28 (Suppl. 04) 9-17
    CrossrefPubMedGoogle Scholar
  • 20 Cha HR, Chang SY, Chang JH , et al. Downregulation of Th17 cells in the small intestine by disruption of gut flora in the absence of retinoic acid. J Immunol 2010; 184 (12) 6799-6806
    CrossrefPubMedGoogle Scholar
  • 21 Ivanov II, Atarashi K, Manel N , et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009; 139 (3) 485-498
    CrossrefPubMedGoogle Scholar
  • 22 Gaboriau-Routhiau V, Rakotobe S, Lécuyer E , et al. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity 2009; 31 (4) 677-689
    CrossrefPubMedGoogle Scholar
  • 23 Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI. Human nutrition, the gut microbiome and the immune system. Nature 2011; 474 (7351) 327-336
    CrossrefPubMedGoogle Scholar
  • 24 Reddy BS, Pleasants JR, Wostmann BS. Effect of intestinal microflora on iron and zinc metabolism, and on activities of metalloenzymes in rats. J Nutr 1972; 102 (1) 101-107
    PubMedGoogle Scholar
  • 25 Qin J, Li R, Raes J , et al; MetaHIT Consortium. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464 (7285) 59-65
    CrossrefPubMedGoogle Scholar
  • 26 Byrne CS, Chambers ES, Morrison DJ, Frost G. The role of short chain fatty acids in appetite regulation and energy homeostasis. Int J Obes 2015; 39 (9) 1331-1338
    CrossrefPubMedGoogle Scholar
  • 27 Ríos-Covián D, Ruas-Madiedo P, Margolles A, Gueimonde M, de Los Reyes-Gavilán CG, Salazar N. Intestinal short chain fatty acids and their link with diet and human health. Front Microbiol 2016; 7: 185
    PubMedGoogle Scholar
  • 28 Bird JJ, Brown DR, Mullen AC , et al. Helper T cell differentiation is controlled by the cell cycle. Immunity 1998; 9 (2) 229-237
    CrossrefPubMedGoogle Scholar
  • 29 Peng L, He Z, Chen W, Holzman IR, Lin J. Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier. Pediatr Res 2007; 61 (1) 37-41
    CrossrefPubMedGoogle Scholar
  • 30 Jung TH, Park JH, Jeon WM, Han KS. Butyrate modulates bacterial adherence on LS174T human colorectal cells by stimulating mucin secretion and MAPK signaling pathway. Nutr Res Pract 2015; 9 (4) 343-349
    CrossrefPubMedGoogle Scholar
  • 31 Fukuda S, Toh H, Hase K , et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 2011; 469 (7331) 543-547
    CrossrefPubMedGoogle Scholar
  • 32 Fox CJ, Hammerman PS, Thompson CB. Fuel feeds function: energy metabolism and the T-cell response. Nat Rev Immunol 2005; 5 (11) 844-852
    CrossrefPubMedGoogle Scholar
  • 33 Michalek RD, Rathmell JC. The metabolic life and times of a T-cell. Immunol Rev 2010; 236: 190-202
    CrossrefPubMedGoogle Scholar
  • 34 Hofmann AF. The enterohepatic circulation of bile acids in mammals: form and functions. Front Biosci (Landmark Ed) 2009; 14: 2584-2598
    PubMedGoogle Scholar
  • 35 Patel AK, Singhania RR, Pandey A, Chincholkar SB. Probiotic bile salt hydrolase: current developments and perspectives. Appl Biochem Biotechnol 2010; 162 (1) 166-180
    CrossrefPubMedGoogle Scholar
  • 36 Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 2006; 47 (2) 241-259
    CrossrefPubMedGoogle Scholar
  • 37 Degirolamo C, Rainaldi S, Bovenga F, Murzilli S, Moschetta A. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. Cell Reports 2014; 7 (1) 12-18
    CrossrefPubMedGoogle Scholar
  • 38 Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. Bile acids and the gut microbiome. Curr Opin Gastroenterol 2014; 30 (3) 332-338
    CrossrefPubMedGoogle Scholar
  • 39 Islam KB, Fukiya S, Hagio M , et al. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology 2011; 141 (5) 1773-1781
    CrossrefPubMedGoogle Scholar
  • 40 Kakiyama G, Pandak WM, Gillevet PM , et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol 2013; 58 (5) 949-955
    CrossrefPubMedGoogle Scholar
  • 41 Bajaj JS, Ridlon JM, Hylemon PB , et al. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol 2012; 302 (1) G168-G175
    CrossrefPubMedGoogle Scholar
  • 42 Bajaj JS, Hylemon PB, Ridlon JM , et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol 2012; 303 (6) G675-G685
    CrossrefPubMedGoogle Scholar
  • 43 Bajaj JS, Heuman DM, Hylemon PB , et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 2014; 60 (5) 940-947
    CrossrefPubMedGoogle Scholar
  • 44 Tyler AD, Smith MI, Silverberg MS. Analyzing the human microbiome: a “how to” guide for physicians. Am J Gastroenterol 2014; 109 (7) 983-993
    CrossrefPubMedGoogle Scholar
  • 45 Rastogi G, Sani R. Molecular techniques to assess microbial community structure, function, and dynamics in the environment. In: Ahmad I, Ahmad F, Pichtel J, , eds. Microbes and Microbial Technology. New York: Springer; 2011: 29-57
    CrossrefGoogle Scholar
  • 46 Fraher MH, O'Toole PW, Quigley EM. Techniques used to characterize the gut microbiota: a guide for the clinician. Nat Rev Gastroenterol Hepatol 2012; 9 (6) 312-322
    CrossrefPubMedGoogle Scholar
  • 47 Song SJ, Amir A, Metcalf J , et al. Preservation methods differ in fecal microbiome stability, affecting suitability for field studies. MSystem 2016; 1: 1-12
    PubMedGoogle Scholar
  • 48 Nechvatal JM, Ram JL, Basson MD , et al. Fecal collection, ambient preservation, and DNA extraction for PCR amplification of bacterial and human markers from human feces. J Microbiol Methods 2008; 72 (2) 124-132
    CrossrefPubMedGoogle Scholar
  • 49 Stearns JC, Lynch MD, Senadheera DB , et al. Bacterial biogeography of the human digestive tract. Sci Rep 2011; 1: 170
    CrossrefPubMedGoogle Scholar
  • 50 Clarridge III JE. Impact of 16S rRNA gene sequence analysis for identification of bacteria on clinical microbiology and infectious diseases. Clin Microbiol Rev 2004; 17 (4) 840-862
    CrossrefPubMedGoogle Scholar
  • 51 Schloss PD, Westcott SL. Assessing and improving methods used in operational taxonomic unit-based approaches for 16S rRNA gene sequence analysis. Appl Environ Microbiol 2011; 77 (10) 3219-3226
    CrossrefPubMedGoogle Scholar
  • 52 Hehemann JH, Correc G, Barbeyron T, Helbert W, Czjzek M, Michel G. Transfer of carbohydrate-active enzymes from marine bacteria to Japanese gut microbiota. Nature 2010; 464 (7290) 908-912
    Google Scholar
  • 53 Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med 2015; 372 (16) 1539-1548
    CrossrefPubMedGoogle Scholar
  • 54 Surawicz CM, Brandt LJ, Binion DG , et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108 (4) 478-498 , quiz 499
    CrossrefPubMedGoogle Scholar
  • 55 van Nood E, Vrieze A, Nieuwdorp M , et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368 (5) 407-415
    CrossrefPubMedGoogle Scholar
  • 56 Cruchet S, Furnes R, Maruy A , et al. The use of probiotics in pediatric gastroenterology: a review of the literature and recommendations by Latin-American experts. Paediatr Drugs 2015; 17 (3) 199-216
    CrossrefPubMedGoogle Scholar
  • 57 Tursi A, Brandimarte G, Papa A , et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2010; 105 (10) 2218-2227
    CrossrefPubMedGoogle Scholar
  • 58 Turnbaugh PJ, Hamady M, Yatsunenko T , et al. A core gut microbiome in obese and lean twins. Nature 2009; 457 (7228) 480-484
    Google Scholar
  • 59 Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444 (7122) 1027-1031
    CrossrefPubMedGoogle Scholar
  • 60 Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 2005; 102 (31) 11070-11075
    CrossrefPubMedGoogle Scholar
  • 61 Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444 (7122) 1022-1023
    CrossrefPubMedGoogle Scholar
  • 62 Raman M, Ahmed I, Gillevet PM , et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2013; 11 (7) 868-75 .e1, 3
    CrossrefPubMedGoogle Scholar
  • 63 Olsson R, Danielsson A, Järnerot G , et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991; 100 (5 Pt 1) 1319-1323
    CrossrefPubMedGoogle Scholar
  • 64 Schrumpf E, Elgjo K, Fausa O, Gjone E, Kolmannskog F, Ritland S. Sclerosing cholangitis in ulcerative colitis. Scand J Gastroenterol 1980; 15 (6) 689-697
    CrossrefPubMedGoogle Scholar
  • 65 Lichtman SN, Keku J, Clark RL, Schwab JH, Sartor RB. Biliary tract disease in rats with experimental small bowel bacterial overgrowth. Hepatology 1991; 13 (4) 766-772
    CrossrefPubMedGoogle Scholar
  • 66 Lichtman SN, Wang J, Clark RL. A microcholangiographic study of liver disease models in rats. Acad Radiol 1995; 2 (6) 515-521
    CrossrefPubMedGoogle Scholar
  • 67 Lichtman SN, Keku J, Schwab JH, Sartor RB. Evidence for peptidoglycan absorption in rats with experimental small bowel bacterial overgrowth. Infect Immun 1991; 59 (2) 555-562
    PubMedGoogle Scholar
  • 68 Bharucha AE, Jorgensen R, Lichtman SN, LaRusso NF, Lindor KD. A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000; 95 (9) 2338-2342
    CrossrefPubMedGoogle Scholar
  • 69 Lichtman SN, Okoruwa EE, Keku J, Schwab JH, Sartor RB. Degradation of endogenous bacterial cell wall polymers by the muralytic enzyme mutanolysin prevents hepatobiliary injury in genetically susceptible rats with experimental intestinal bacterial overgrowth. J Clin Invest 1992; 90 (4) 1313-1322
    CrossrefPubMedGoogle Scholar
  • 70 Lichtman SN, Keku J, Schwab JH, Sartor RB. Hepatic injury associated with small bowel bacterial overgrowth in rats is prevented by metronidazole and tetracycline. Gastroenterology 1991; 100 (2) 513-519
    CrossrefPubMedGoogle Scholar
  • 71 Yamada S, Ishii M, Liang LS, Yamamoto T, Toyota T. Small duct cholangitis induced by N-formyl L-methionine L-leucine L-tyrosine in rats. J Gastroenterol 1994; 29 (5) 631-636
    CrossrefPubMedGoogle Scholar
  • 72 Sasatomi K, Noguchi K, Sakisaka S, Sata M, Tanikawa K. Abnormal accumulation of endotoxin in biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 1998; 29 (3) 409-416
    CrossrefPubMedGoogle Scholar
  • 73 Tabibian JH, O'Hara SP, Trussoni CE , et al. Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis. Hepatology 2016; 63 (1) 185-196
    CrossrefPubMedGoogle Scholar
  • 74 Sabino J, Vieira-Silva S, Machiels K , et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut 2016; 65 (10) 1681-1689
    CrossrefPubMedGoogle Scholar
  • 75 Kummen M, Holm K, Anmarkrud JA , et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut 2016; gutjnl-2015-310500
    PubMedGoogle Scholar
  • 76 Quraishi MN, Sergeant M, Kay G , et al. The gut-adherent microbiota of PSC-IBD is distinct to that of IBD. Gut 2016; DOI: ;gutjnl-2016-311915.
    PubMedGoogle Scholar
  • 77 Rühlemann MC, Heinsen FA, Zenouzi R, Lieb W, Franke A, Schramm C. Faecal microbiota profiles as diagnostic biomarkers in primary sclerosing cholangitis. Gut 2016; gutjnl-2016-312180
    PubMedGoogle Scholar
  • 78 Torres J, Bao X, Goel A , et al. The features of mucosa-associated microbiota in primary sclerosing cholangitis. Aliment Pharmacol Ther 2016; 43 (7) 790-801
    CrossrefPubMedGoogle Scholar
  • 79 Rossen NG, Fuentes S, Boonstra K , et al. The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured Clostridiales II. J Crohn's Colitis 2015; 9 (4) 342-348
    PubMedGoogle Scholar
  • 80 Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, Calignano A. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol 2011; 17 (12) 1519-1528
    CrossrefPubMedGoogle Scholar
  • 81 Bowlus CL. Cutting edge issues in primary sclerosing cholangitis. Clin Rev Allergy Immunol 2011; 41 (2) 139-150
    CrossrefPubMedGoogle Scholar
  • 82 Rankin JG, Boden RW, Goulston SJ, Morrow W. The liver in ulcerative colitis; treatment of pericholangitis with tetracycline. Lancet 1959; 2 (7112) 1110-1112
    PubMedGoogle Scholar
  • 83 Mistilis SP, Skyring AP, Goulston SJ. Effect of long-term tetracycline therapy, steroid therapy and colectomy in pericholangitis associated with ulcerative colitis. Australas Ann Med 1965; 14 (4) 286-294
    PubMedGoogle Scholar
  • 84 Tada S, Ebinuma H, Saito H, Hibi T. Therapeutic benefit of sulfasalazine for patients with primary sclerosing cholangitis. J Gastroenterol 2006; 41 (4) 388-389
    CrossrefPubMedGoogle Scholar
  • 85 Kozaiwa K, Tajiri H, Sawada A , et al. Three paediatric cases of primary sclerosing cholangitis treated with ursodeoxycholic acid and sulphasalazine. J Gastroenterol Hepatol 1998; 13 (8) 825-829
    CrossrefPubMedGoogle Scholar
  • 86 Vleggaar FP, Monkelbaan JF, van Erpecum KJ. Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study. Eur J Gastroenterol Hepatol 2008; 20 (7) 688-692
    CrossrefPubMedGoogle Scholar
  • 87 Cox KL, Cox KM. Oral vancomycin: treatment of primary sclerosing cholangitis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1998; 27 (5) 580-583
    CrossrefPubMedGoogle Scholar
  • 88 Tabibian JH, Weeding E, Jorgensen RA , et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther 2013; 37 (6) 604-612
    CrossrefPubMedGoogle Scholar
  • 89 Boner AL, Peroni D, Bodini A, Delaini G, Piacentini G. Azithromycin may reduce cholestasis in primary sclerosing cholangitis: a case report and serendipitous observation. Int J Immunopathol Pharmacol 2007; 20 (4) 847-849
    PubMedGoogle Scholar
  • 90 Färkkilä M, Karvonen AL, Nurmi H , et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 2004; 40 (6) 1379-1386
    CrossrefPubMedGoogle Scholar
  • 91 Silveira MG, Torok NJ, Gossard AA , et al. Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study. Am J Gastroenterol 2009; 104 (1) 83-88
    CrossrefPubMedGoogle Scholar
  • 92 Tabibian JH, Gossard A, El-Youssef M , et al. Prospective clinical trial of rifaximin therapy for patients with primary sclerosing cholangitis. Am J Ther 2014; DOI: 10.1097/MJT.0000000000000102.
    PubMedGoogle Scholar
  • 93 Davies YK, Cox KM, Abdullah BA, Safta A, Terry AB, Cox KL. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr 2008; 47 (1) 61-67
    CrossrefPubMedGoogle Scholar
  • 94 Dudley MN, Quintiliani R, Nightingale CH, Gontarz N. Absorption of vancomycin. Ann Intern Med 1984; 101 (1) 144
    PubMedGoogle Scholar
  • 95 Matzke GR, Halstenson CE, Olson PL, Collins AJ, Abraham PA. Systemic absorption of oral vancomycin in patients with renal insufficiency and antibiotic-associated colitis. Am J Kidney Dis 1987; 9 (5) 422-425
    CrossrefPubMedGoogle Scholar
  • 96 Matzke GR, Zhanel GG, Guay DR. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet 1986; 11 (4) 257-282
    CrossrefPubMedGoogle Scholar
  • 97 Abarbanel DN, Seki SM, Davies Y , et al. Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis. J Clin Immunol 2013; 33 (2) 397-406
    CrossrefPubMedGoogle Scholar
  • 98 Shimizu M, Iwasaki H, Mase S, Yachie A. Successful treatment of primary sclerosing cholangitis with a steroid and a probiotic. Case Rep Gastroenterol 2012; 6 (2) 249-253
    CrossrefPubMedGoogle Scholar